How to Improve Radiotherapy Decisions in Endometrial Cancer How to Improve Radiotherapy Decisions in Endometrial Cancer
Radiotherapy decisions should be made using refined genomic guidance, as recommended by 2021 updated international guidelines, to better identify patients with molecularly aggressive disease.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 25, 2024 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Hormonal Birth Control Doesn ’ t Deserve Its Bad Reputation
Almost two-thirds of U.S. women of reproductive age use some kind of contraception, according to the latest federal data. And millions of them use methods that contain hormones, including birth control pills, intrauterine devices (IUDs), rings, implants, injections, and patches.
Although the specifics vary from method to method, hormonal birth control generally works by halting ovulation and/or changing conditions in the uterus or cervix to prevent pregnancy. And it works well: efficacy rates approach 100% when these methods are used correctly.
[time-brightcove not-tgx=”true”]
But hormonal birth control ...
Source: TIME: Health - April 3, 2024 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Evergreen Explainer healthscienceclimate Source Type: news
Kate Middleton Had to Tell Her Kids About Her Cancer Diagnosis. These Parents Know What That ’ s Like
After weeks of fevered speculation, Catherine, Princess of Wales, revealed on Mar. 22 that she was absent from the public eye not because she was having marital problems or growing out a bad haircut, but because she was being treated for cancer. She and her husband had, she said, “taken time to explain everything to George, Charlotte and Louis in a way that is appropriate for them, and to reassure them that I am going to be OK.” Even before her announcement, however, many cancer survivors who were also parents had already guessed at the truth. The silence and delay tactics looked familiar, because they had done...
Source: TIME: Health - March 28, 2024 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized Cancer Source Type: news
Black Women More Likely to Die From Endometrial Cancer Black Women More Likely to Die From Endometrial Cancer
New research confirms racial disparities in survival outcomes and representation in clinical trials among Black and White women with a common subtype of endometrial cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 26, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Lenvatinib-Pembrolizumab Combo Misses on Survival in Endometrial Cancer Trial
(MedPage Today) -- SAN DIEGO -- A combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) failed to meet survival endpoints compared with chemotherapy as first-line therapy for patients with advanced or recurrent endometrial cancer... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 20, 2024 Category: Hematology Source Type: news
Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer
(MedPage Today) -- SAN DIEGO -- Rucaparib (Rubraca) maintenance after first- or second-line chemotherapy improved progression-free survival (PFS) in patients with metastatic or recurrent endometrial cancer, a small phase II randomized trial showed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 19, 2024 Category: Hematology Source Type: news
RUBY:'A Huge Win' for Patients With Endometrial Cancer RUBY:'A Huge Win' for Patients With Endometrial Cancer
The RUBY trial shows that adding an immune checkpoint inhibitor to chemotherapy improved overall survival by over 1 year for women with advanced or recurrent endometrial cancer.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 19, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer
Saturday, GSK plc GSK announced overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial of Jemperli (dostarlimab) for primary advanced or recurrent endometrial cancer, paving the way for a potential label…#gskplc #gsk #rubyengoten6 #fda #jemperli #jemperlipluszejula #zejula (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2024 Category: Consumer Health News Source Type: news
Immune Checkpoint Inhibitor-Chemo Combo Boosts OS in Advanced Endometrial Cancer
(MedPage Today) -- SAN DIEGO -- The addition of an immune checkpoint inhibitor (ICI) to chemotherapy up front improved overall survival (OS) in patients with advanced or recurrent endometrial cancer, regardless of mismatch repair (MMR) status... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 18, 2024 Category: Hematology Source Type: news
I thought I was menopausal but it turned out to be 'terminal' womb cancer. Now I've beaten the disease
Carol Kernaghan, 63, from Frome in Somerset, initially dismissed the blood spotting in her pants and pain in her hip thinking she was 'just menopausal'. But tests revealed she had endometrial cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - February 26, 2024 Category: Consumer Health News Source Type: news
Women ’ s health at work is a UNISON priority says conference
Women’s health at work was a key focus of UNISON’s national women’s conference, held in Brighton last week.
Delegates passed motions with a specific focus on reproductive health, including one that called on the union to investigate and report on the needs of women workers in relation to endometriosis, menopause and menstruation.
Another motion called on the union to campaign for paid leave for pregnancy loss. During the debate, several speakers shared their experiences at work after suffering miscarriages. One delegate described her line manager as saying to her: “Why are you crying? It wasn’t a real baby, j...
Source: UNISON Health care news - February 20, 2024 Category: UK Health Authors: Janey Starling Tags: Article News 2024 women's conference Menopause Source Type: news
ACS: Cancer mortality declines, but incidence rates rise
Overall cancer mortality continues to decline, but incidence rates are up, according to a January 17 report by the American Cancer Society (ACS).
The report shows that there have been more than four million fewer deaths from cancer in the U.S. since 1991. However, it also showed increased incidence for six of the top 10 cancers as the projected number of new diagnoses is over two million for the first time.
“I think we’re all grappling with what the environmental factor that is changing the cancer incidence and mortality among the young," said ACS chief scientific officer William Dahut, MD, at a press conference.
AC...
Source: AuntMinnie.com Headlines - January 17, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties CT Breast Imaging Source Type: news
EU gives green light to new drug to treat endometrial cancer
The new drug treatment for uterine cancer, which is already in use in France on an early access scheme, will be used in combination with chemotherapy. British pharmaceutical company GlaxoSmithKline (GSK) announced on Monday that it has received European approval to market its treatment for…#gsk #europeancommission #jemperli (Source: Reuters: Health)
Source: Reuters: Health - December 26, 2023 Category: Consumer Health News Source Type: news
GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer Study
GSK plc GSK announced headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy,…#gskplc #gsk #rubyengoten6 #rsvvaccinemarket #mss (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2023 Category: Consumer Health News Source Type: news
Endometrial Cancer Therapy Combo Fails 1L Treatment Trial Endometrial Cancer Therapy Combo Fails 1L Treatment Trial
Merck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line treatment for a type of cancer in the uterus lining.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
